Medistim

Regulatory Filings • Oct 19, 2021

Pivotal consensus statement for Medistim’s transit time flow technology (TTFM) published in Circulation

Pivotal consensus statement for Medistim’s transit time flow technology (TTFM) published in Circulation

(Oslo, 19th of October 2021) Medistim ASA (OSE: MEDI) is a niche market leader within ultrasound technology with headquarters in Oslo, Norway. Medistim develops and commercializes medical equipment for use within cardiac, vascular and transplant surgery. Today, Medistim announces that their Transit Time Flow Measurement (TTFM) technology receives strong support from leading experts, in a new publication in top journal Circulation.

Circulation – the official journal of the American Heart Association – and one of the highest ranked journals in cardiology and cardiovascular medicine, published a consensus paper by 19 of the world’s highest renowned specialists in coronary artery bypass surgery (CABG) on October 5th. The study describes a systematic review to identify best practice evidence for guideline development published the last 20 years. Over 2,200 articles identified, more than 1,550 of them screened, and 38 of them included in this review paper. The expert consensus process resulted in a new flowchart for decision making guidance to cardiac surgeons on how to utilize TTFM during surgery. The first of the 10 consensus statements and justifications states “TTFM should be used in every CABG case”. The panelists agree “that quality assurance in CABG procedures should be established as a key component to improve patient outcomes”.

“This is a pivotal paper for Medistim that clearly graces all of our initiatives to position our MiraQTM technology for routine use during CABG surgery” says Medistim President and CEO, Kari E. Krogstad. “Having our technology in focus in one of the world’s most renowned cardiovascular journals gives us a strong sense of moving in the right direction with our strategy. Our REQUEST study published in 2020 is one of the key papers they have assessed to underpin the importance of routine use of quality assessment. We believe that this strong advocacy will not only exert peer influence within the community of cardiac surgeons, but further, that it may pave the way for new and enhanced clinical guidelines worldwide.”

View the Circulation publication here: https://www.ahajournals.org/doi/epub/10.1161/CIRCULATIONAHA.121.054311

About Medistim:

Medistim was established in 1984 and has a track record of profitable growth over the past 20 years. The company is a pioneer within its segment and continues to invest in new product development. Medistim has wholly owned subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark, and Norway, in addition to the about 50 distributors in Europe, Asia, Middle East, Africa, Canada and South America. For more information, visit the Medistim home page: www.medistim.com

For more information, contact:

President and CEO, Kari E. Krogstad, Medistim ASA

Tel: + 47 918 38 110

Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA

Tel: + 47 906 59 940

Email: thomas.jakobsen@medistim.com